Episode Details

Retatrutide, the "Triple G" (GLP-1, GIP, glucagon receptor agonist) weight loss medication, has been generating buzz for years, but when will it actually be FDA approved? In this episode, Lisa Oldson, MD breaks down the real timeline based on Eli Lilly's latest announcements, including the difference between the obesity and diabetes submission tracks, what standard versus priority FDA review could mean for approval dates, and why compounded versions of retatrutide are not the real thing. She also shares an update on the latest phase 3 data, walks through a patient's real struggle with a Zepbound plateau while waiting for retatrutide to arrive, and offers this week's Next Best Action for anyone stuck between a current medication and a future one.

Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. 

We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. 

Also, we’d be grateful if you'd follow us and share our podcast with your friends & family. We’re here to help you live longer, healthier, and lose weight the SMART way! 

This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

The Smart Weight Loss Coaching Podcast is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication.